Ventyx Biosciences Inc VTYX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
-
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
-
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
-
Ventyx Biosciences Announces Departure of Chief Financial Officer
-
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
-
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
-
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
-
Uber, Datadog stocks gain, Air Products shares lead S&P 500 losers and other stocks on the move
Trading Information
- Previous Close Price
- $2.39
- Day Range
- $2.32–2.44
- 52-Week Range
- $1.79–36.19
- Bid/Ask
- $2.38 / $2.41
- Market Cap
- $166.78 Mil
- Volume/Avg
- 1.0 Mil / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- https://www.ventyxbio.com
Comparables
Valuation
|
Metric
|
VTYX
|
MGNX
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.59 | 3.30 | 0.68 |
Price/Sales | — | 4.80 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VTYX
MGNX
PRLD
Financial Strength
|
Metric
|
VTYX
|
MGNX
|
PRLD
|
|---|---|---|---|
Quick Ratio | 13.23 | 2.53 | 7.71 |
Current Ratio | 14.19 | 2.71 | 7.83 |
Interest Coverage | — | −128.87 | — |
Quick Ratio
VTYX
MGNX
PRLD
Profitability
|
Metric
|
VTYX
|
MGNX
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −45.56% | −59.21% | −40.98% |
Return on Equity (Normalized) | −50.18% | −120.96% | −46.70% |
Return on Invested Capital (Normalized) | −53.41% | −102.88% | −44.57% |
Return on Assets
VTYX
MGNX
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xwqrkxjfck | Jhsbx | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dnrfwxcg | Dgbmffr | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dkgrvmwc | Tzwqbh | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kltylcy | Mssbz | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Cjjbvwnfl | Fjx | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Zfnlvfqq | Wjl | $28.0 Bil | |||
| Moderna Inc
MRNA
| Dnzjnvw | Cdzjh | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Sfgmhjq | Chkfw | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yxfjgrjx | Dnjypj | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Zzzlmdmfz | Pfrdcbj | $12.6 Bil |
United States